Estimating the extent of vaccine-derived poliovirus infection

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Wringe, Alison ^a   Fine, Paul E M ^a   Sutter, Roland W ^b   Kew, Olen M ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CAMBODIA; CHILD; CHINA; DISEASE SURVEILLANCE; EPIDEMIC; ERADICATION THERAPY; FLACCID PARALYSIS; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFANT; MADAGASCAR; MAJOR CLINICAL STUDY; PHILIPPINES; POLIOMYELITIS; POLIOMYELITIS VIRUS; RISK ASSESSMENT; VACCINE DERIVED POLIOMYELITIS; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS TRANSMISSION; VIRUS VIRULENCE; DOMINICAN REPUBLIC; EGYPT; GENETICS; HAITI; HEALTH SURVEY; IMMUNOLOGY; INDONESIA; ISOLATION AND PURIFICATION; PHYSIOLOGY; PRESCHOOL CHILD; SOCIAL CLASS; STATISTICS; VIROLOGY;

POLIOVIRUS;

ADOLESCENT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DOMINICAN REPUBLIC; EGYPT; GENETIC VARIATION; HAITI; HUMANS; INDONESIA; INFANT; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; POPULATION SURVEILLANCE; SOCIAL CLASS;

EID: 56149088488     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003433     Document Type: Article

References (63)

1. Yang CF, Naguib T, Yang SJ, Nasr E, Jorba J, et al. (2003) Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 77: 8366-8377.
2. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, et al. (1999) Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265: 178-184.
3. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, et al. (1998) Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 36: 2893-2899.
4. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI (2000) Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol 74: 7381-7390.
5. (2003) Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003. MMWR Morb Mortal Wkly Rep 52: 913-916.
6. (2002) Expanding contributions of the global laboratory network for poliomyelitis eradication, 2000-2001. Wkly Epidemiol Rec 77: 133-137.
7. (2006) Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep 55: 1093-1097.
8. Liang X, Zhang Y, Xu W, Wen N, Zuo S, et al. (2006) An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis 194: 545-551.
9. Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, et al. (2004) Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 78: 13512-13521.
10. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, Randriamanalina B, Guillot S, et al. (2003) Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 9: 885-887.
11. Estivariz CF, Watkins MA, Handoko D, Rusipah R, Deshpande J, et al. (2008) A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis 197: 347-354.
12. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, et al. (2002) Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296: 356-359.
13. Rakoto-Andrianarivelo M, Gumede N, Jegouic S, Balanant J, Andriamamonjy SN, et al. (2008) Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis 197: 1427-1435.
14. (2007) Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 56: 996-1001.
15. Chiba Y, Kobayashi M, Chosa T, Yamamoto T, Endo K, et al. (2003) Molecular epidemiology of type 2 vaccine-associated paralytic poliomyelitis in china. Jpn J Infect Dis 56: 181-183.
16. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, et al. (2002) Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76: 6791-6799.
17. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, et al. (1997) Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71: 7758-7768.
18. Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, et al. (2000) Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 38: 3729-3734.
19. Shulman LM, Manor Y, Sofer D, Handsher R, Swartz T, et al. (2006) Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS ONE 1: e69.
20. Blomqvist S, Savolainen C, Laine P, Hirttio P, Lamminsalo E, et al. (2004) Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol 78: 4876-4883.
21. Fine PE, Oblapenko G, Sutter RW (2004) Polio control after certification: major issues outstanding. Bull World Health Organ 82: 47-52.
22. Fine PE, Sutter RW, Orenstein WA (2001) Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel) 105: 129-147; discussion 149-150.
23. Dowdle W, van der Avoort H, de Gourville E, Delpeyroux F, Desphande J, et al. (2006) Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal 26: 1449-1469.
24. Sutter R, Kew O, Cochi S (2003) Poliovirus vaccine- live. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia: W.B Saunders Company.
25. John TJ, Jayabal P (1972) Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 96: 263-269.
26. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, et al. (2007) Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369: 1356-1362.
27. Patriarca PA, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 13: 926-939.
28. Bernier RH (1984) Some observations on poliomyelitis lameness surveys. Rev Infect Dis 6 Suppl 2: S371-375.
29. Melnick JL, Ledinko N (1953) Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period; the ratio of inapparent infection to clinical poliomyelitis. Am J Hyg 58: 207-222.
30. Martín J, Dunn G, Hull R, Patel V, Minor PD (2000) Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 74: 3001-3010.
31. Yang CF, Chen HY, Jorba J, Sun HC, Yang SJ, et al. (2005) Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 79: 12623-12634.
32. Jorba J, Campagnoli R, De L, Kew O (2008) Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 82: 4429-4440.
33. Fine PE, Carneiro IA (1999) Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 150: 1001-1021.
34. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, et al. (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14: 568-579.
35. Patriarca PA, Sutter RW, Oostvogel PM (1997) Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 175 Suppl 1: S165-172.
36. Nathanson N, Martín JR (1979) The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 110: 672-692.
37. Gelfand HM, Leblanc DR, Fox JP, Conwell DP (1957) Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg 65: 367-385.
38. Bouchard MJ, Lam DH, Racaniello VR (1995) Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69: 4972-4978.
39. Ren RB, Moss EG, Racaniello VR (1991) Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65: 1377-1382.
40. Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, et al. (1989) Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63: 1338-1344.
41. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW (1989) Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol 63: 4949-4951.
42. Andrus JK, Strebel PM, de Quadros CA, Olive JM (1995) Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bull World Health Organ 73: 33-40.
43. Nkowane BM, Wassilak SG, Orenstein WA, Bart KJ, Schonberger LB, et al. (1987) Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. Jama 257: 1335-1340.
44. Joce R, Wood D, Brown D, Begg N (1992) Paralytic poliomyelitis in England and Wales, 1985-91. Bmj 305: 79-82.
45. de Oliveira LH, Struchiner CJ (2000) Vaccine-associated paralytic poliomyelitis in Brazil, 1989-1995. Rev Panam Salud Publica 7: 219-224.
46. Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW (2002) Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 80: 210-216.
47. Minor PD, Dunn G (1988) The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J Gen Virol 69(Pt 5): 1091-1096.
48. (2001) Update: Outbreak of poliomyelitis-Dominican Republic and Haiti, 2000-2001. MMWR Morb Mortal Wkly Rep 50: 855-856.
49. Vinjé J, Gregoricus N, Martín J, Gary HE Jr, Caceres VM, et al. (2004) Isolation and characterization of circulating type 1 vaccine-derived poliovirus from sewage and stream waters in Hispaniola. J Infect Dis 189: 1168-1175.
50. (2008) Core Health Indicators. In: WHO, ed. Geneva.
51. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Oro JB, et al. (1967) Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 86: 112-136.
52. (2003) Progress toward poliomyelitis eradication-Egypt, 2002. MMWR Morb Mortal Wkly Rep 52: 252-255.
53. (2004) Progress towards poliomyelitis eradication - Egypt, 2003-2004. MMWR Morb Mortal Wkly Rep 53: 820-822.
54. UN-Habitat Population Statistics. In: UN-Habitat, ed. Geneva.
55. Aylward RB, Mansour E, El Said AO, Haridi A, Abu El Kheir A, et al. (1997) The eradication of poliomyelitis in Egypt: critical factors affecting progress to date. J Infect Dis 175 Suppl 1: S56-61.
56. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59: 587-635.
57. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, et al. (2003) Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol 77: 12460-12465.
58. MacCallum FO (1971) Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B) 310: 72-85.
59. MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martín J, et al. (2004) Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363: 1509-1513.
60. Wood DJ, Sutter RW, Dowdle WR (2000) Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Organ 78: 347-357.
61. (2003) Poliovirus infections in four unvaccinated children-Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep 54: 1053-1055.
62. (2001) Acute flaccid paralysis associated with circulating vaccine-derived poliovirus-Philippines, 2001. MMWR Morb Mortal Wkly Rep 50: 874-875.
63. (2005) Poliomyelitis surveillance weekly bulletin. Polio Weekly Bulletin. Manila.